Kissei Pharmaceutical And Wakamoto Pharmaceutical Co-Promote Salagen
This article was originally published in PharmAsia News
Kissei Pharmaceutical and Wakamoto Pharmaecutical signed an agreement May 2 to co-promote Kissei's Salagen (pilocarpine), a drug used to treat dryness of the mouth and throat that may occur after radiation treatment for cancer of the head and neck, and to patients with Sjogren's syndrome. Kissei obtained the drug's exclusive development and marketing right in Japan from MGI Pharma, a subsidiary of Eisai. According to the agreement, Kissei and Wakamoto will promote the drug to assigned medical facilities, but Kissei will continue to solely handle manufacturing, marketing and distribution. (Click here for more - Japanese language
You may also be interested in...
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.